Alpha-1-antitrypsin is produced by human neutrophil granulocytes and their precursors and liberated during granule exocytosis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Alpha-1-antitrypsin is produced by human neutrophil granulocytes and their precursors and liberated during granule exocytosis. / Clemmensen, Stine N; Jacobsen, Lars C; Rørvig, Sara; Askaa, Bjarke; Christenson, Karin; Iversen, Martin; Jørgensen, Marianne H; Larsen, Maria T; van Deurs, Bo; Østergaard, Ole; Heegaard, Niels H; Cowland, Jack B; Borregaard, Niels.
In: European Journal of Haematology, Vol. 86, No. 6, 01.06.2011, p. 517-30.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Alpha-1-antitrypsin is produced by human neutrophil granulocytes and their precursors and liberated during granule exocytosis
AU - Clemmensen, Stine N
AU - Jacobsen, Lars C
AU - Rørvig, Sara
AU - Askaa, Bjarke
AU - Christenson, Karin
AU - Iversen, Martin
AU - Jørgensen, Marianne H
AU - Larsen, Maria T
AU - van Deurs, Bo
AU - Østergaard, Ole
AU - Heegaard, Niels H
AU - Cowland, Jack B
AU - Borregaard, Niels
N1 - © 2011 John Wiley & Sons A/S.
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Alpha-1-antitrypsin (A1AT) is an important inhibitor of neutrophil proteases including elastase, cathepsin G, and proteinase 3. Transcription profiling data suggest that A1AT is expressed by human neutrophil granulocytes during all developmental stages. A1AT has hitherto only been found associated with azurophile granules in neutrophils indicative of A1AT expression being restricted to the promyelocyte stage. We examined the localization and production of A1AT in healthy donor neutrophils and found A1AT to be a constituent of all granule subtypes and to be released from neutrophils following stimulation. A1AT is produced at all stages of myeloid maturation in the bone marrow. The production increases as neutrophils enter circulation and increases further upon migration to tissues as observed in skin windows and when blood neutrophils are incubated with granulocyte colony-stimulating factor. Neutrophils from patients with A1AT-deficiency carrying the (PI)ZZ mutation in the A1AT gene appeared structurally and functionally normal, but A1AT produced in leukocytes of these patients lacked the ability to bind proteases efficiently. We conclude that A1AT generation and release from neutrophils add significantly to the antiprotease levels in tissues during inflammation. Impaired binding of neutrophil A1AT to serine proteases in patients with (PI)ZZ mutations may enhance their susceptibility to the development of emphysema.
AB - Alpha-1-antitrypsin (A1AT) is an important inhibitor of neutrophil proteases including elastase, cathepsin G, and proteinase 3. Transcription profiling data suggest that A1AT is expressed by human neutrophil granulocytes during all developmental stages. A1AT has hitherto only been found associated with azurophile granules in neutrophils indicative of A1AT expression being restricted to the promyelocyte stage. We examined the localization and production of A1AT in healthy donor neutrophils and found A1AT to be a constituent of all granule subtypes and to be released from neutrophils following stimulation. A1AT is produced at all stages of myeloid maturation in the bone marrow. The production increases as neutrophils enter circulation and increases further upon migration to tissues as observed in skin windows and when blood neutrophils are incubated with granulocyte colony-stimulating factor. Neutrophils from patients with A1AT-deficiency carrying the (PI)ZZ mutation in the A1AT gene appeared structurally and functionally normal, but A1AT produced in leukocytes of these patients lacked the ability to bind proteases efficiently. We conclude that A1AT generation and release from neutrophils add significantly to the antiprotease levels in tissues during inflammation. Impaired binding of neutrophil A1AT to serine proteases in patients with (PI)ZZ mutations may enhance their susceptibility to the development of emphysema.
U2 - 10.1111/j.1600-0609.2011.01601.x
DO - 10.1111/j.1600-0609.2011.01601.x
M3 - Journal article
C2 - 21477074
VL - 86
SP - 517
EP - 530
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 6
ER -
ID: 33750643